CCME Global Ltd
Incorporated in 1992, Genesis IBRC India Ltd (Formerly SSK Lifestyles Limited) is in the business of Biotechnology.
- Market Cap ₹ 529 Cr.
- Current Price ₹ 117
- High / Low ₹ 185 / 20.2
- Stock P/E
- Book Value ₹ 7.39
- Dividend Yield 0.00 %
- ROCE %
- ROE -0.31 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 62.8% over last quarter.
Cons
- Stock is trading at 15.8 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| 4.33 | |
| 4.15 | |
| Operating Profit | 0.18 |
| OPM % | 4.16% |
| 0.01 | |
| Interest | 0.03 |
| Depreciation | 0.09 |
| Profit before tax | 0.07 |
| Tax % | 128.57% |
| -0.03 | |
| EPS in Rs | -0.02 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | % |
| 3 Years: | 122% |
| 1 Year: | 507% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| Equity Capital | 13.00 |
| Reserves | -3.39 |
| 1.48 | |
| 1.21 | |
| Total Liabilities | 12.30 |
| 2.07 | |
| CWIP | 1.30 |
| Investments | 0.00 |
| 8.93 | |
| Total Assets | 12.30 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| 1.68 | |
| -4.66 | |
| 3.00 | |
| Net Cash Flow | 0.02 |
| Free Cash Flow | 1.68 |
| CFO/OP | 933% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| Debtor Days | 119.70 |
| Inventory Days | 68.92 |
| Days Payable | 17.87 |
| Cash Conversion Cycle | 170.75 |
| Working Capital Days | 399.56 |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Benefit Expenses INR ・Standalone data |
|
||||||||||
| Purchase of Traded Goods INR ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
12h - Submitted Secretarial Compliance Audit Report for FY ended March 31, 2026.
-
Results For The Quarter And Financial Year Ended March 31 2026
1d - Board approved FY26 audited results; 3.225 crore shares allotted via preferential issue raising ₹32.25 crore.
-
Statement Of Deviation For The Quarter And Financial Year Ended March 31, 2026
1d - Quarterly no-deviation report for ₹32.25 crore preferential issue; no funds utilized till 31 March 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On May 29, 2026
1d - Board approved FY26 audited results and preferential allotment of 3.225 crore shares raising ₹32.25 crore.
-
Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On May 29, 2026 To Consider And Approve Financial Results For The Quarter And Financial Year Ended March 31, 2026 And Other Matters
22 May - Board meeting on May 29, 2026 to approve audited Q4 and FY2026 financial results.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Profile:[1]
a) Aquaculture Probiotic: Proteomix Protein Balanced Gel, Yuccagen Ammonia Controller, Growfast Gen Single Cell Protein, Progutgen Aquaculture Gut Probiotic, Rhodogen PS -Water Probiotic
b) Aqua Feed Supplement: Moultigen Aqua EDTA Aqua Culture, Vitagen C Aqua Culture and Zeo-Gen Multi Mineral Additive Granules from India
c) Aquaculture Water Sanitizer: Sangen- Broad Spectrum Sanitizer
d) Soil Probiotic: Genpro Wat Soil Probiotic
e) Aquaculture: Vibrio Controller In Shrimp Culture